Building a concentration progression strategy Rather than jumping to your target concentration immediately, strategic progression improves outcomes and safety
At one year, 81% of patients receiving liraglutide plus riskfactor modification were free from AFib or atrial flutter, compared with 54% of patients in the riskfactor modificationonly group
As the global burden of obesity and cardiometabolic disease continues to rise, the adoption of incretin-based therapies is accelerating, driving substantial growth in the market across both diabetes care and weight-management segments
In fact, there is a strong correlation in the level of glycated Lp(a) and the severity of hyperglycemia observed in poorly controlled type 2 diabetes
The severity distribution across trials was heavily skewed mild
While longer-term randomised controlled trials are needed, the evidence supports considering tirzepatide or semaglutide over liraglutide or DPP-4 inhibitors in patients with MASLD at risk of fibrosis progression